FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions discloses a liquid composition containing GLP-1 agonist and/or its pharmaceutically acceptable salt and differing by the fact that the composition contains methionine, wherein the composition is substantially free from histidine and EDTA, and wherein the GLP-1 agonist is present in an amount of 0.01 mg/ml to 1.5 mg/ml, whereas using them for treating diabetes mellitus and obesity.
EFFECT: declared group of inventions possesses high stability.
29 cl, 6 dwg, 8 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITION CONTAINING AGONIST GLP-1, INSULIN AND METHIONINE | 2010 |
|
RU2537239C2 |
| INSULIN PREPARATION CONTAINING METHIONINE | 2010 |
|
RU2540485C2 |
| STABILISED COMPOUNDS OF EXENDIN-4 | 2003 |
|
RU2376314C2 |
| COMBINATION OF INSULIN AND GLP-1 AGONIST | 2014 |
|
RU2682671C2 |
| COMBINATION OF INSULIN AND GLP-1 AGONIST | 2009 |
|
RU2532378C2 |
| NOVEL INSULIN DERIVATIVES WITH STRONGLY SLOWED PROFILE TIME/ACTION | 2009 |
|
RU2529952C2 |
| NOVEL INSULIN DERIVATIVES WITH EXTREMELY DELAYED TIME/ACTION PROFILE | 2009 |
|
RU2524423C2 |
| PEN-TYPE INJECTOR WITH WINDOW ELEMENT | 2013 |
|
RU2651907C2 |
| DRUG DELIVERY DEVICE FOR INTRODUCTION OF PRESET DRUG DOSE | 2012 |
|
RU2603289C2 |
| SYNTHESIS OF LIXISENATIDE WITH CAPPING | 2019 |
|
RU2782772C2 |
